Head and Neck-Journal for the Sciences and Specialties of the Head and Neck最新文献

{"title":"Long-Term Outcomes of IDH2-Mutant Sinonasal Carcinomas Compared With IDH2-Wild Type Sinonasal Undifferentiated Carcinoma.","authors":"Daniel W Scholfield, Lucas Axiotakis, Robbie Woods, Katherine Tai, Alana Eagan, Lillian A Boe, Emma Finnegan, Kenric Tam, Jennifer Cracchiolo, Lara Dunn, Nancy Lee, Ian Ganly, Marc A Cohen, Snjezana Dogan","doi":"10.1002/hed.70495","DOIUrl":"https://doi.org/10.1002/hed.70495","url":null,"abstract":"<p><strong>Background: </strong>Sinonasal carcinomas are aggressive and often locally invasive at presentation, with no universally accepted treatment approach. Histopathologic IDH2-mutant status appears to be associated with improved treatment response and survival. However, the clinical significance of histopathologic classification among IDH2-mutant sinonasal carcinomas, as well as that of IDH2 mutation status within SNUC, remains unclear and long-term clinical outcome data are limited.</p><p><strong>Methods: </strong>Records from a prospectively maintained skull-base database at a large, tertiary care hospital system from 1986 to 2024 were reviewed. Patients with a diagnosis of SNUC or sinonasal tumor of any histopathology positive for IDH2 R172 mutation were identified. SMARCB1-deficient, SMARCA4-deficient, NUT sinonasal carcinomas, and other small round cell mimickers were excluded. After histopathologic confirmation, 22 IDH2-mutant SNUC, 14 IDH2-mutant non-SNUC, and 8 IDH2-wildtype SNUC cases were amenable to comprehensive clinicopathologic data review. A presence of IDH2 R172 and pathogenic TP53 mutations was determined by molecular testing and/or by immunohistochemistry.</p><p><strong>Results: </strong>The median age at diagnosis was 58 years and 61% of patients were male. The majority of patients presented with T4b disease (41% of IDH2-mutant SNUC; 57% of IDH2-mutant non-SNUC; 75% of IDH2-wildtype SNUC; p = 0.3). There was no significant difference in the proportion of patients presenting with orbital invasion (55% IDH2-mutant SNUC; 64% IDH2-mutant non-SNUC; 75% of IDH2-wildtype SNUC; p = 0.7) or intracranial invasion (82% IDH2-mutant SNUC; 79% IDH2-mutant non-SNUC; 75% of IDH2-wildtype SNUC; p = 0.7). On histopathology, there was no significant difference in perineural invasion and margin status between the three subgroups (p > 0.6). A greater proportion of IDH2-mutant non-SNUCs had TP53 mutations (67%) than IDH2-mutant SNUC (31%) and IDH2-wildtype SNUC (29%) (p = 0.13). Across the cohort, 41% of patients received neoadjuvant chemotherapy, with a partial response by RECIST criteria in 94% of patients across the subgroups. Median follow-up was 28 months (IQR 11-64 months). 5-year DSS of 73% in IDH2-mutant SNUC, 75% in IDH2-mutant non-SNUC and 80% in IDH2-wildtype SNUC (p = 0.78). 5-year RFS was 53% in IDH2-mutant SNUC, 48% in IDH2-mutant non-SNUC and 43% in IDH2-wildtype SNUC (p = 0.78).</p><p><strong>Conclusion: </strong>Upfront assessment of IDH2 mutation status in sinonasal carcinoma patients may be warranted to select patients for clinical trials with IDH-inhibitors. However, no significant differences in the extent of disease at presentation or response to induction chemotherapy were observed according to histopathologic classification among IDH2-mutant sinonasal carcinomas or IDH2 mutation status within SNUC. Larger series are required to determine the prognostic significance of IDH2 mutation status in sinonasal carcinoma patients","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs vs. Wide Local Excision for Early-Stage (AJCC 0-II) Cutaneous Head and Neck Melanoma: A Meta-Analysis.","authors":"Anna Ardoin, Srivatsa Surya Vasudevan, Kashmira C Rodrigues, Christopher J Vance, Jason D Pou, Cherie-Ann O Nathan","doi":"10.1002/hed.70511","DOIUrl":"https://doi.org/10.1002/hed.70511","url":null,"abstract":"<p><strong>Objective: </strong>To compare oncologic outcomes of Mohs micrographic surgery (MMS) versus wide local excision (WLE) in the management of cutaneous head and neck melanoma (CHNM), including melanoma in situ (MIS) and Stage I-II invasive disease.</p><p><strong>Study design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>PubMed, Embase, ScienceDirect, and Web of Science were systematically searched for studies published between January 2000 and March 2026 that reported outcomes of MMS versus WLE for CHNM, including MIS and AJCC Stage I-II invasive disease. Outcomes of interest were recurrence, tumor upstaging, and secondary excision rates, which were pooled using a random-effects meta-analysis model. Sensitivity analyses were performed to assess robustness, and meta-regression was used to explore sources of heterogeneity.</p><p><strong>Results: </strong>Of 691 records screened, 23 studies comprising 7090 cases of early-stage (AJCC Stage 0-II) CHNM were included. The median age was 68.8 years, and 68.4% of patients were male. For MIS, the pooled local recurrence rate was lower after MMS (1.7%; 95% CI: 0.7-4.4) than after WLE (6.3%; 95% CI: 3.4-11.4). Upstaging to invasive melanoma was likewise less frequent with MMS (3.3%; 95% CI: 2.1-4.9) than with WLE (8.1%; 95% CI: 4.3-14.8), as was secondary surgical excision (1.2%; 95% CI: 0.1-10.3 vs. 9.7%; 95% CI: 3.0-27.0). Among Stage I-II cases, the pooled recurrence rate was 1.3% (95% CI: 0.3-4.6) after MMS and 8.8% (95% CI: 1.3-41.0) after WLE.</p><p><strong>Conclusion: </strong>Although none of the between-group differences reached statistical significance, MMS showed consistently favorable trends in local control and in reducing upstaging and secondary procedures for early-stage CHNM. These findings support consideration of MMS in appropriately selected patients.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"De-Escalation or Dose Redistribution? Interpreting the 'Safe Omission' of Postoperative Neck Irradiation in pN0 Oral Cavity Cancer\".","authors":"Mathilde Mirallié, Yassine Alachram, Margaux Lafaurie, Emilien Chabrillac, Anouchka Modesto, Agnès Dupret-Bories","doi":"10.1002/hed.70498","DOIUrl":"https://doi.org/10.1002/hed.70498","url":null,"abstract":"","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-Escalation or Dose Redistribution? Interpreting the \"Safe Omission\" of Postoperative Neck Irradiation in pN0 Oral Cavity Cancer.","authors":"Pareeksit Rajkumar Bagchi, Padmakar Baviskar, Swathi Yennemadi","doi":"10.1002/hed.70497","DOIUrl":"https://doi.org/10.1002/hed.70497","url":null,"abstract":"","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shaving Versus Resection on Recurrent Laryngeal Nerve in Thyroid Cancer Surgeries: A Systematic Review and Meta-Analysis.","authors":"Eric Tran, Jordan Kankam, Liana Salehian, Harry May, Daniel Stuart, Yusuf Dundar","doi":"10.1002/hed.70509","DOIUrl":"https://doi.org/10.1002/hed.70509","url":null,"abstract":"<p><strong>Background: </strong>Management of recurrent laryngeal nerve (RLN) invasion by thyroid cancer remains controversial between shaving the tumor and resecting it. We compared oncological and functional outcomes of the two techniques.</p><p><strong>Methods: </strong>Following PRISMA guidelines, three reviewers searched seven databases for studies from 1995 to 2024 comparing shaving and resection of the RLN. Outcomes explored were overall survival, recurrence, preservation of vocal cord function, maximum phonation time, and other treatment-related morbidities if provided.</p><p><strong>Results: </strong>A total of 13 retrospective cohorts (532 patients) met inclusion criteria. Overall survival and tracheotomy requirements did not differ between groups. Shaving was associated with lower recurrence (p = 0.007), better vocal fold mobility (p < 0.0001), and longer maximum phonation time (p = 0.04).</p><p><strong>Conclusion: </strong>This analysis showed that shaving was associated with better functional outcomes and lower recurrence than resection, without a survival difference. Because shaved patients had less advanced disease, these associations may reflect selection bias; prospective studies are needed.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Outcomes Following Endovascular Management for Carotid Blowout Syndrome: A Multi-Institutional Observational Cohort Study.","authors":"Szu-Cheng Huang, Yi-Chieh Lee, Yu-Chen Tsai, Chen-June Seak, Chieh-Ching Yen","doi":"10.1002/hed.70488","DOIUrl":"https://doi.org/10.1002/hed.70488","url":null,"abstract":"<p><strong>Background: </strong>Carotid blowout syndrome (CBS) is a life-threatening complication of head and neck cancer (HNC). This study evaluated clinical outcomes and prognostic factors in patients with HNC who presented to the emergency department (ED) with CBS and underwent endovascular management.</p><p><strong>Methods: </strong>We conducted a retrospective, multi-institutional observational study across four hospitals in Taiwan from January 1, 2011, to December 31, 2023. Adult patients with HNC who presented to the ED with bleeding suggestive of CBS on computed tomography angiography underwent endovascular therapy and had the diagnosis confirmed by digital subtraction angiography were included. The primary endpoint was in-hospital mortality. Independent prognostic factors were identified using multivariable logistic regression, and a predictive nomogram was constructed and internally validated by bootstrap resampling.</p><p><strong>Results: </strong>A total of 348 patients were included. Most were male (93.7%), had Stage IV disease (74.7%), and were treated with arterial embolization (93.4%). In-hospital mortality occurred in 57 patients (16.4%). The estimated 30-day and 1-year survival rates were 84.8% and 51.7%, respectively. In multivariable analysis, vasopressor use (odds ratio [OR], 6.54), failed hemostasis (OR, 4.68), tracheostomy status (OR, 2.04), multivessel involvement (OR, 1.98), and lower systolic blood pressure (OR, 0.99 per mmHg) were independently associated with in-hospital mortality. The nomogram showed moderate discrimination with a C-statistic of 0.73.</p><p><strong>Conclusions: </strong>Among patients with HNC presenting to the ED with CBS and undergoing endovascular management, in-hospital mortality remained substantial. A nomogram incorporating readily available clinical and imaging variables may assist early risk stratification after ED presentation.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Early Post-Treatment Circulating Tumor Tissue Modified Viral HPV DNA Testing in HPV-Associated Oropharyngeal Cancer.","authors":"Scott A Roof, James Jabalee, Eleni M Rettig, Ryan M Sicard, Rocco Ferrandino, Sida Chen, Marshall R Posner, Krzysztof J Misiukiewicz, Eric M Genden, Raymond L Chai, John Sims, Elaine Thrash, Scott J Stern, Bethany Sargent, Noah S Kalman, Sreenija Yarlagadda, John M Kaczmar, Adam Raben, Lydia Clements, Neil Hockstein, Mihir Bhayani, Abie H Mendelsohn, Glenn J Hanna","doi":"10.1002/hed.70483","DOIUrl":"https://doi.org/10.1002/hed.70483","url":null,"abstract":"<p><strong>Background: </strong>TTMV-HPV DNA testing is prognostic during post-treatment surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but the significance of testing before conventional 3-month response assessment remains unclear.</p><p><strong>Methods: </strong>We retrospectively analyzed 332 patients across 8 US sites with biopsy-proven HPV-associated OPSCC who underwent initial definitive treatment and had ≥ 1 TTMV-HPV DNA test performed 1 to 89 days after treatment completion. Event-free survival (EFS) was evaluated using a 90-day landmark approach.</p><p><strong>Results: </strong>The first TTMV-HPV DNA test obtained 1-89 days after treatment was negative in 310 patients (93%), indeterminate in 3 (1%), and positive in 19 (6%). Among 59 patients with repeat testing after an initially negative result, 57 (97%) remained negative and 2 (3%) converted to positive; both patients who converted subsequently developed recurrence. Of 13 patients with an initially positive result and sufficient follow-up for trajectory analysis, 6 (46%) subsequently resolved to negative and none developed recurrence, whereas 7 (54%) remained persistently positive and 6 (86%) developed recurrence. In a 90-day landmark analysis, the last early post-treatment TTMV-HV DNA result was associated with subsequent event-free survival.</p><p><strong>Conclusions: </strong>TTMV-HPV DNA testing during the 1-89-day post-treatment interval was associated with subsequent clinical outcomes in HPV-associated OPSCC. Persistent positivity identified patients at increased risk, whereas positive results that resolved were not followed by recurrence in this cohort.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconstruction of Total Laryngectomy Defect Using Parascapular Free Flap: Case Series.","authors":"Zaid Al-Qurayshi, Evgeniya Molotkova, Patrik Pipkorn","doi":"10.1002/hed.70502","DOIUrl":"https://doi.org/10.1002/hed.70502","url":null,"abstract":"<p><strong>Background: </strong>Reconstruction of total laryngectomy defects with vascularized tissue helps minimize the risk of pharyngocutaneous fistula development. Few studies have assessed outcomes following reconstruction with a parascapular free flap.</p><p><strong>Methods: </strong>We identified 28 patients who underwent laryngectomy with parascapular free flap reconstruction between 2020 and 2024. Chart review was directed toward operative characteristics and postoperative outcomes, which were summarized using descriptive statistics.</p><p><strong>Results: </strong>Thirteen out of 28 patients (46%) underwent salvage laryngectomy. Average operative time was 6.6 (±1.2) hours. Donor site morbidity was low; one patient experienced delayed wound dehiscence that was managed conservatively. Six patients developed pharyngocutaneous fistula; one patient required surgical intervention. The length of hospital stay ranged from 5 to 22 days, and the duration of postoperative nil per os status ranged from 7 to 56 days.</p><p><strong>Conclusions: </strong>Our experience demonstrates that the parascapular free flap is a viable option for reconstruction of defects secondary to laryngectomy.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-Analysis.","authors":"Samiya Rahim, Muskan Kumari, Eisha Abid, Rida Khan Hoti, Fatima Sajjad, Fatima Tu Zahra Hafeez Khan, Muskan Hotak, Salma Afridi, Ahmad Ali, Hassaan Muhammad, Malaika Saqib, Fazia Khattak, Umar Anwar, Marwa Nasar, Nisar Ud Din, Aamir Ahmed, Hassan Hanif, Syed Ikram Ullah, Abdullah Afridi","doi":"10.1002/hed.70485","DOIUrl":"https://doi.org/10.1002/hed.70485","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin- and carboplatin-based regimens are widely used in the treatment of head and neck squamous cell carcinoma (HNSCC), yet comparative evidence on survival and toxicity outcomes remains limited. While cisplatin is standard in many settings, carboplatin is often preferred in patients with comorbidities or impaired renal function. This systematic review and meta-analysis aimed to synthesize available evidence comparing cisplatin versus carboplatin in HNSCC.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library from inception to February 2026. Randomized and observational studies comparing cisplatin- and carboplatin-based regimens in HNSCC were included. Primary outcomes were overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival at 1, 3, and 5 years and distant metastasis-free survival (DMFS) at 1 and 3 years. Secondary outcomes include grade ≥ 3 toxicities. Data were pooled using random-effects meta-analysis.</p><p><strong>Results: </strong>Eight studies comprising 1044 patients were included, including four recently published studies not previously pooled in head-to-head analyses. Pooled analyses showed no statistically significant differences between cisplatin and carboplatin in OS, PFS, LRRFS, or DMFS overall. Subgroup analyses across 1, 3, and 5-year follow-up intervals likewise demonstrated no significant differences for most outcomes. The only significant finding was a modest difference in 5-year LRRFS favoring cisplatin, based on only two studies. No statistically significant differences were observed in grade ≥ 3 anemia, leukopenia, thrombocytopenia, or nausea/vomiting.</p><p><strong>Conclusions: </strong>Cisplatin and carboplatin-based regimens yield largely comparable survival and toxicity outcomes in HNSCC. Treatment selection should be guided by patient comorbidities and tolerability.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Acceptability of Remote Symptom Monitoring and Wearable Activity Monitoring in Head and Neck Cancer Patients: A Mixed Methods Pilot Study.","authors":"Krupal B Patel, Carley Geiss, Taylor Welniak, Yvelise Rodriguez, Hayden Fulton, Noel Jessin, Jameel Muzaffar, Kedar Kirtane, Christine H Chung, George Yang, Michelle Echevarria, James Caudell, Xuefeng Wang, Heather S L Jim, Kea Turner, Yi Luo, Brian D Gonzalez","doi":"10.1002/hed.70491","DOIUrl":"https://doi.org/10.1002/hed.70491","url":null,"abstract":"<p><strong>Background: </strong>Treatment-related symptoms and toxicities are common in Head and Neck Cancer (HNC) patients undergoing chemoradiation (CRT). This underscores the importance of timely interventions and effective symptom and toxicity monitoring strategies to mitigate complications and improve quality of life (QoL). Traditional clinician and care team assessments often underreport patient symptoms, leading to urgent care and emergency room admissions, referred to as health care utilization (HCU). In contrast, electronically captured patient-reported outcomes (ePROs) are associated with improved survival, better health-related QoL, and lower HCU. Wearable activity monitors (WAMs) offer an additional method for continuous monitoring, enabling clinicians to detect symptoms and toxicities more efficiently and respond rapidly to patient needs.</p><p><strong>Methods: </strong>12 HNC patients were assessed with ePROs and WAMs during CRT.</p><p><strong>Results: </strong>HNC patients undergoing CRT are receptive to ePRO and WAM-based monitoring.</p><p><strong>Conclusions: </strong>HNC patients are receptive to participating in ePROs and WAM studies.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}